News

UNC researchers find final pieces to the circadian clock puzzle

UNC researchers find final pieces to the circadian clock puzzle

Sixteen years after scientists found the genes that control the circadian clock in all cells, the lab of UNC’s Aziz Sancar, MD, PhD, discovered the mechanisms responsible for keeping the clock in sync.

UNC researchers find final pieces to the circadian clock puzzle - Read More…

Damania appointed Assistant Dean for Research

Damania appointed Assistant Dean for Research

Blossom Damania, PhD, professor of microbiology and immunology, has been named Assistant Dean for Research at the UNC School of Medicine, effective immediately.

Damania appointed Assistant Dean for Research - Read More…

Basch contributes to new ASCO guidelines for prostate cancer treatment

Basch contributes to new ASCO guidelines for prostate cancer treatment

New clinical guidelines have been announced for the treatment of men with metastatic castration-resistant prostate cancer (CRPC) by the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO). Ethan Basch, MD, director of the Cancer Outcomes Research Program at UNC Lineberger Comprehensive Cancer Center, served as the co-chair of the ASCO/CCO expert panel that developed the guideline.

Basch contributes to new ASCO guidelines for prostate cancer treatment - Read More…

UNC researchers find new genetic target for a different kind of cancer drug

UNC researchers find new genetic target for a different kind of cancer drug

Upstream of the proteins that cancer cells use to proliferate sits RBM4, a gene-splicing protein that UNC researcher Zefeng Wang, PhD, discovered is drastically reduced in human lung and breast cancer cells.

UNC researchers find new genetic target for a different kind of cancer drug - Read More…

Popular cancer drug target implicated in cardiovascular defects

Popular cancer drug target implicated in cardiovascular defects

Research led by UNC’s Kathleen Caron, PhD, shows that halting the protein CXCR7 leads to over activation of adrenomedullin, a hormone needed at proper levels for normal cardiovascular development

Popular cancer drug target implicated in cardiovascular defects - Read More…

Changing the face of clinical trials

Changing the face of clinical trials

UNC Lineberger secures three major NCI grants to advance the nation’s clinical trials program.

Changing the face of clinical trials - Read More…

Anders presents at 13th Annual Round Asia Oncology Forum

Anders presents at 13th Annual Round Asia Oncology Forum

Carey Anders, MD, UNC Lineberger member and associate professor, was a presenter and moderator at The 13th Annual Round Asia Oncology Forum (RAOF) in Hong Kong on August 29 - 30, 2014. The theme of this year’s forum was “Expanding our armory in personalized cancer treatment.”

Anders presents at 13th Annual Round Asia Oncology Forum - Read More…

Eshelman gives $3 million gift to Center for Integrative Chemical Biology and Drug Discovery

Eshelman gives $3 million gift to Center for Integrative Chemical Biology and Drug Discovery

The UNC Eshelman School of Pharmacy has received a $3 million gift from philanthropist and pharmaceutical-industry executive Fred Eshelman. Eshelman’s gift will support the work of the School’s Center for Integrative Chemical Biology and Drug Discovery, led by UNC Lineberger member Stephen Frye, PhD. The center is dedicated to evaluating and developing potential drug targets discovered by UNC faculty.

Eshelman gives $3 million gift to Center for Integrative Chemical Biology and Drug Discovery - Read More…

Swenberg and colleagues publish in DNA Repair

James Swenberg, PhD, DVM, DACVP, Environmental Science & Engineering, Cancer Genetics, and additional co-authors have published "The endogenous exposome" in the July 2014 issue of DNA Repair. In the review, authors focused on the endogenous exposome, the DNA damage that arises from the production of endogenous electrophilic molecules in cells.

Swenberg and colleagues publish in DNA Repair - Read More…

Major receives National Cancer Institute Grant

Major receives National Cancer Institute Grant

The National Cancer Institute has awarded Ben Major, PhD, assistant professor of Cell Biology and Physiology, University of North Carolina at Chapel Hill and UNC Lineberger Comprehensive Cancer Center, with an R21 award of $275,000 to support his project “Mass spectrometry-coupled hypermorphic functional genomics”. The goal of the research is to develop gain-of-function screening technology to connect gene overexpression with signal transduction in cancer.

Major receives National Cancer Institute Grant - Read More…

2014 University Cancer Research Fund Innovation Awards announced

Six researchers have been awarded 2014 University Cancer Research Fund (UCRF) Innovation Awards for promoting innovative and new ideas in cancer research at the University of North Carolina at Chapel Hill.

2014 University Cancer Research Fund Innovation Awards announced - Read More…

Field of Hope honors cancer survivors and raises money for Kay Yow Cancer Fund

Field of Hope honors cancer survivors and raises money for Kay Yow Cancer Fund

UNC Health Care and Rex Healthcare co-sponsored “Field of Hope” at the Durham Bulls game on Saturday, August 23 with a portion of special ticket sales going to the Kay Yow Cancer Fund.

Field of Hope honors cancer survivors and raises money for Kay Yow Cancer Fund - Read More…

Lung Cancer Initiative of NC Hosts 4th Lung Cancer Advocacy Summit

Lung Cancer Initiative of NC Hosts 4th Lung Cancer Advocacy Summit

The Lung Cancer Initiative of NC hosted a statewide Lung Cancer Summit on August 23 at the N.C. Cancer Hospital. Lung cancer advocates were bolstered with training, resources, knowledge and the courage to take action. UNC Lineberger Comprehensive Cancer Center was the Host Sponsor of the event.

Lung Cancer Initiative of NC Hosts 4th Lung Cancer Advocacy Summit - Read More…

The Ras Tracker

The Ras Tracker

For more than 20 years, Sharon Campbell, PhD, has been studying Ras, a protein implicated in 30 percent of all cancers. Now she’s on the hunt for alternative ways to shut the protein down.

The Ras Tracker - Read More…

UNC researchers trade lab coats for running shoes

UNC researchers trade lab coats for running shoes

Kirsten Bryant, PhD, was recently recognized by the Pancreatic Cancer Action Network for her dual role in the fight against pancreatic cancer.

UNC researchers trade lab coats for running shoes - Read More…

UNC Lineberger researchers develop new approach to identify “drivers” of cancer

UNC Lineberger Comprehensive Cancer Center researchers have developed a new integrated approach to pinpoint the genetic “drivers” of cancer, uncovering eight genes that could be viable for targeted breast cancer therapy. The study, published online August 24 in Nature Genetics, was authored by Michael Gatza, PhD, lead author and post-doctoral research associate; Grace Silva, graduate student; Joel Parker, PhD, director of bioinformatics, UNC Lineberger; Cheng Fan, research associate; and senior author Chuck Perou, PhD, professor of genetics and pathology.

UNC Lineberger researchers develop new approach to identify “drivers” of cancer - Read More…

UNC researchers lead project to sequence rare kidney cancer

UNC researchers lead project to sequence rare kidney cancer

An international scientific collaboration led by researchers at UNC has revealed new insights into the unique genetic alterations that contribute to a rare form of kidney cancer.

UNC researchers lead project to sequence rare kidney cancer - Read More…

Innocenti Receives R21 Grant to Personalize Angiogenesis Inhibitors to Individual Cancer Patients

Innocenti Receives R21 Grant to Personalize Angiogenesis Inhibitors to Individual Cancer Patients

Angiogenesis inhibitors are a class of drugs commonly used in cancer therapy. However, there isn’t a way to identify patients who will benefit the most from treatment with these drugs. A new $275,000 grant could help Federico Innocenti, MD, PhD, and his team identify such patients based on their genetic profile.

Innocenti Receives R21 Grant to Personalize Angiogenesis Inhibitors to Individual Cancer Patients - Read More…